Compare $ERNA vs $LIMN | Chartloom

Compare

$ERNA vs $LIMN

Ernexa Therapeutics Inc · Liminatus Pharma Inc

ERNA

Ernexa Therapeutics Inc

LIMN

Liminatus Pharma Inc

Compare $ERNA vs $LIMN

Comparing Ernexa Therapeutics Inc and Liminatus Pharma Inc

ERNAErnexa Therapeutics Inc

LIMNLiminatus Pharma Inc

ERNAErnexa Therapeutics Inc

Market cap

$3M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-91.7%

52W performance

-93.0%

FCF yield

-316.2%

LIMNLiminatus Pharma Inc

Market cap

$253M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-88.3%

52W performance

-95.3%

FCF yield

-1.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ERNA

LIMN

Detailed metrics comparison

ERNA

Ernexa Therapeutics Inc

LIMN

Liminatus Pharma Inc

Market Cap

ERNA$3M

LIMN$253M

Enterprise Value

ERNA$-2M

LIMN$251M

Price

ERNA$2.40

LIMN$3.76

P/E Ratio

ERNAN/A

LIMNN/A

P/S Ratio

ERNA8.30x

LIMN0.00x

EV/Sales

ERNA0.09x

LIMN0.00x

EV/EBITDA

ERNA0.00x

LIMN0.00x

P/B Ratio

ERNA1.51x

LIMN17.43x

P/FCF Ratio

ERNAN/A

LIMNN/A

EV/FCF

ERNA0.22x

LIMN-62.96x

PEG Ratio

ERNAN/A

LIMNN/A

Forward P/E (NTM)

ERNAN/A

LIMNN/A

Forward P/S (NTM)

ERNAN/A

LIMNN/A

Revenue (TTM)

ERNA$0

LIMN$0

Revenue Growth (YoY)

ERNAN/A

LIMNN/A

Forward Rev Growth

ERNA0.0%

LIMN0.0%

Gross Margin (TTM)

ERNA83.5%

LIMN0.0%

Operating Margin (TTM)

ERNA0.0%

LIMN0.0%

EBITDA Margin (TTM)

ERNA0.0%

LIMN0.0%

Net Margin (TTM)

ERNA0.0%

LIMN0.0%

FCF Margin (TTM)

ERNAN/A

LIMNN/A

Net Income (TTM)

ERNA$-3M

LIMN$-13M

FCF (TTM)

ERNA$-9M

LIMN$-4M

EPS (TTM)

ERNA$0.00

LIMN-$12.94

ROE (TTM)

ERNA-16940.0%

LIMN0.0%

ROA (TTM)

ERNA-22854.0%

LIMN-62234.0%

ROIC (TTM)

ERNA-15802.0%

LIMN0.0%

Cash

ERNA$5M

LIMN$3M

Debt

ERNA$250K

LIMN$1M

Net Cash/Debt

ERNA$5M

LIMN$2M

Current Ratio (TTM)

ERNA2.01x

LIMN1.12x

Quick Ratio (TTM)

ERNA1.74x

LIMN0.99x

Debt/Equity (TTM)

ERNA0.08x

LIMN4.80x

Debt/Assets (TTM)

ERNA0.0%

LIMN0.0%

Interest Coverage (TTM)

ERNAN/A

LIMNN/A

Net Debt/EBITDA (TTM)

ERNA0.00x

LIMN0.00x

Beta

ERNA2.68

LIMN0.75

52W Performance

ERNA-93.0%

LIMN-95.3%

YTD Performance

ERNA-91.7%

LIMN-88.3%

% from 52W High

ERNA-96.6%

LIMN-97.3%

% from 52W Low

ERNA13.2%

LIMN14.3%

Asset Turnover (TTM)

ERNA0.02x

LIMN0.00x

FCF Yield (TTM)

ERNA-316.2%

LIMN-1.6%

Earnings Yield (TTM)

ERNA-97.9%

LIMN-5.0%

Dividend Yield (TTM)

ERNA0.4%

LIMNN/A

Rule of 40

ERNA0.0

LIMN0.0

EV/GP/RG

ERNAN/A

LIMNN/A

Ticker research

View ERNA research View LIMN research

Metric	ERNA Ernexa Therapeutics Inc	LIMN Liminatus Pharma Inc
Market & Valuation
Market Cap	$3M	$253M
Enterprise Value	$-2M	$251M
Price	$2.40	$3.76
P/E Ratio	N/A	N/A
P/S Ratio	8.30x	0.00x
EV/Sales	0.09x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.51x	17.43x
P/FCF Ratio	N/A	N/A
EV/FCF	0.22x	-62.96x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	0.0%	0.0%
Profitability
Gross Margin (TTM)	83.5%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-3M	$-13M
FCF (TTM)	$-9M	$-4M
EPS (TTM)	$0.00	-$12.94
ROE (TTM)	-16940.0%	0.0%
ROA (TTM)	-22854.0%	-62234.0%
ROIC (TTM)	-15802.0%	0.0%
Financial Health
Cash	$5M	$3M
Debt	$250K	$1M
Net Cash/Debt	$5M	$2M
Current Ratio (TTM)	2.01x	1.12x
Quick Ratio (TTM)	1.74x	0.99x
Debt/Equity (TTM)	0.08x	4.80x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.68	0.75
52W Performance	-93.0%	-95.3%
YTD Performance	-91.7%	-88.3%
% from 52W High	-96.6%	-97.3%
% from 52W Low	13.2%	14.3%
Efficiency & Yields
Asset Turnover (TTM)	0.02x	0.00x
FCF Yield (TTM)	-316.2%	-1.6%
Earnings Yield (TTM)	-97.9%	-5.0%
Dividend Yield (TTM)	0.4%	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ERNA research	View LIMN research

Valuation

P/S Ratio

LIMN

0.00x

ERNA

8.30x

EV/FCF

LIMN

-62.96x

ERNA

0.22x

Growth & revenue

Forward Revenue Growth

ERNA

0.0%

LIMN

0.0%

Profitability & performance

Gross Margin

ERNA

83.5%

LIMN

0.0%

ROE

LIMN

0.0%

ERNA

-16940.0%

FCF Yield %

LIMN

-1.6%

ERNA

-316.2%

52-Week Performance

ERNA

-93.0%

LIMN

-95.3%

Detailed metrics comparison

ERNA

Ernexa Therapeutics Inc

LIMN

Liminatus Pharma Inc

Market Cap

ERNA$3M

LIMN$253M

Enterprise Value

ERNA$-2M

LIMN$251M

Price

ERNA$2.40

LIMN$3.76

P/E Ratio

ERNAN/A

LIMNN/A

P/S Ratio

ERNA8.30x

LIMN0.00x

EV/Sales

ERNA0.09x

LIMN0.00x

EV/EBITDA

ERNA0.00x

LIMN0.00x

P/B Ratio

ERNA1.51x

LIMN17.43x

P/FCF Ratio

ERNAN/A

LIMNN/A

EV/FCF

ERNA0.22x

LIMN-62.96x

PEG Ratio

ERNAN/A

LIMNN/A

Forward P/E (NTM)

ERNAN/A

LIMNN/A

Forward P/S (NTM)

ERNAN/A

LIMNN/A

Revenue (TTM)

ERNA$0

LIMN$0

Revenue Growth (YoY)

ERNAN/A

LIMNN/A

Forward Rev Growth

ERNA0.0%

LIMN0.0%

Gross Margin (TTM)

ERNA83.5%

LIMN0.0%

Operating Margin (TTM)

ERNA0.0%

LIMN0.0%

EBITDA Margin (TTM)

ERNA0.0%

LIMN0.0%

Net Margin (TTM)

ERNA0.0%

LIMN0.0%

FCF Margin (TTM)

ERNAN/A

LIMNN/A

Net Income (TTM)

ERNA$-3M

LIMN$-13M

FCF (TTM)

ERNA$-9M

LIMN$-4M

EPS (TTM)

ERNA$0.00

LIMN-$12.94

ROE (TTM)

ERNA-16940.0%

LIMN0.0%

ROA (TTM)

ERNA-22854.0%

LIMN-62234.0%

ROIC (TTM)

ERNA-15802.0%

LIMN0.0%

Cash

ERNA$5M

LIMN$3M

Debt

ERNA$250K

LIMN$1M

Net Cash/Debt

ERNA$5M

LIMN$2M

Current Ratio (TTM)

ERNA2.01x

LIMN1.12x

Quick Ratio (TTM)

ERNA1.74x

LIMN0.99x

Debt/Equity (TTM)

ERNA0.08x

LIMN4.80x

Debt/Assets (TTM)

ERNA0.0%

LIMN0.0%

Interest Coverage (TTM)

ERNAN/A

LIMNN/A

Net Debt/EBITDA (TTM)

ERNA0.00x

LIMN0.00x

Beta

ERNA2.68

LIMN0.75

52W Performance

ERNA-93.0%

LIMN-95.3%

YTD Performance

ERNA-91.7%

LIMN-88.3%

% from 52W High

ERNA-96.6%

LIMN-97.3%

% from 52W Low

ERNA13.2%

LIMN14.3%

Asset Turnover (TTM)

ERNA0.02x

LIMN0.00x

FCF Yield (TTM)

ERNA-316.2%

LIMN-1.6%

Earnings Yield (TTM)

ERNA-97.9%

LIMN-5.0%

Dividend Yield (TTM)

ERNA0.4%

LIMNN/A

Rule of 40

ERNA0.0

LIMN0.0

EV/GP/RG

ERNAN/A

LIMNN/A

Ticker research

View ERNA research View LIMN research

Metric	ERNA Ernexa Therapeutics Inc	LIMN Liminatus Pharma Inc
Market & Valuation
Market Cap	$3M	$253M
Enterprise Value	$-2M	$251M
Price	$2.40	$3.76
P/E Ratio	N/A	N/A
P/S Ratio	8.30x	0.00x
EV/Sales	0.09x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.51x	17.43x
P/FCF Ratio	N/A	N/A
EV/FCF	0.22x	-62.96x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	0.0%	0.0%
Profitability
Gross Margin (TTM)	83.5%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-3M	$-13M
FCF (TTM)	$-9M	$-4M
EPS (TTM)	$0.00	-$12.94
ROE (TTM)	-16940.0%	0.0%
ROA (TTM)	-22854.0%	-62234.0%
ROIC (TTM)	-15802.0%	0.0%
Financial Health
Cash	$5M	$3M
Debt	$250K	$1M
Net Cash/Debt	$5M	$2M
Current Ratio (TTM)	2.01x	1.12x
Quick Ratio (TTM)	1.74x	0.99x
Debt/Equity (TTM)	0.08x	4.80x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.68	0.75
52W Performance	-93.0%	-95.3%
YTD Performance	-91.7%	-88.3%
% from 52W High	-96.6%	-97.3%
% from 52W Low	13.2%	14.3%
Efficiency & Yields
Asset Turnover (TTM)	0.02x	0.00x
FCF Yield (TTM)	-316.2%	-1.6%
Earnings Yield (TTM)	-97.9%	-5.0%
Dividend Yield (TTM)	0.4%	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ERNA research	View LIMN research